ELI WHITNEY ADVISORY COMMITTEE

of Connecticut Innovations, Incorporated

Minutes – Regular Meeting

Wednesday, June 19, 2019

A regular meeting of the **Eli Whitney Advisory Committee of Connecticut Innovations, Incorporated** (the “Advisory Committee”) was held on June 19, 2019 at the office of Connecticut Innovations, Inc. (“CI”), 865 Brook Street, Rocky Hill, CT.

**1. Call to Order**:

Rafael Santiago, Chairperson of the Advisory Committee, noting the presence of a quorum, called the meeting to order at 3:02 p.m. Advisory Committee members present: Gerry DePardo (by phone), Erik Jansen (by phone), Alan Mendelson (by phone), Tim Shannon (by phone), and Michael Werle (by phone).

Absent: Paul Pescatello

CI Board members attending: Richard Mulready (by phone), and Alex Pencu (by phone).

Staff attending: Matthew Bloom, Daniel Boyle, Brandon Davis, Amanda Hayward (by phone), Heidi Marshall, Peter Longo, Matthew McCooe (by phone), Ted Murphy, Patrick O’Neill, Carrie White, and David Wurzer.

**2. Approval of Minutes:**

Mr. Santiago asked the Advisory Committee members to consider the minutes from the June 6, 2019 regular meeting.

**Upon a motion made by Mr. DePardo, and seconded by Mr. Werle, the Advisory Committee members voted unanimously in favor of approving the minutes, as presented, from the June 6, 2019 regular meeting.**

**3. New Investment Proposal:**

**“Mount Sinai Genomics, Inc. d/b/a Sema4 – Stamford, CT”**

Mr. Wurzer and Ms. White discussed the proposed new investment for Mount Sinai Genomics, Inc. d/b/a Sema4 (the “Company”). Mr. Wurzer stated that Sema4 is a growth stage health intelligence company.

Ms. White asked the Eli Whitney Advisory Committee to enter executive session to discuss Mount Sinai Genomics, Inc. d/b/a Sema4.

**Upon a motion made by Mr. DePardo, and seconded by Mr. Werle, the Advisory Committee members voted unanimously in favor of going into executive session at 3:03 p.m. to discuss financial and/or commercial information and/or trade secrets, regarding Mount Sinai Genomics, Inc. d/b/a Sema4.**

The executive session ended at 3:46 p.m., and the regular meeting was immediately reconvened.

**Upon a motion made by Mr. DePardo, and seconded by Mr. Jansen, the Advisory Committee members voted unanimously in favor of recommending to the Eli Whitney Investment Committee that financing be approved by Connecticut Innovations, Inc. in an amount of up to $5,000,000 for product development, sales and marketing, and working capital for Mount Sinai Genomics, Inc. d/b/a Sema4.**

**4. Other Business:**

**“SecBI – Stamford, CT and Israel”**

Mr. Bloom asked the Eli Whitney Advisory Committee to enter executive session to discuss SecBI.

**Upon a motion made by Mr. Werle, and seconded by Mr. Jansen, the Advisory Committee members voted unanimously in favor of going into executive session at 3:48 p.m. to discuss financial and/or commercial information and/or trade secrets, regarding SecBI.**

The executive session ended at 4:01 p.m., and the regular meeting was immediately reconvened.

**Upon a motion made by Mr. DePardo, and seconded by Mr. Werle, the Advisory Committee members voted unanimously in favor of recommending to the Eli Whitney Investment Committee that Connecticut Innovations remove the previously approved funding requirement for SecBI to hire a 3rd CT-based FTE, prior to funding a second tranche of investment, since the 2nd tranche is now funding a bridge to consider strategic alternatives for SecBI.**

**5. Date of Next Meeting**:

July 11, 2019 at 3:00 p.m.

**6.** **Adjournment**:

**Upon a motion made by Mr. DePardo, and seconded by Mr. Werle, the Advisory Committee members voted unanimously to adjourn the June 19, 2019 regular meeting at 4:03 p.m.**

Respectfully submitted,

Rafael Santiago

Chairperson of the Eli Whitney Advisory Committee